

Study

Adverse events	CSR Fizazzi	Saad 2002 ¹¹⁷	Dearnaley 2003 ⁷⁹	Elomaa 1992 ⁸⁰	KyImala 1997 ⁸³	Small 2003 ⁸⁷	^a Walter 2008 ¹⁶⁰	^a Garcia -Saenz 2007 ¹⁴⁴	^a Oh 2007 ¹⁵²	^a Bamias 2005 ⁶²
Confusional state	13 (1.4)	12 (1.3)	0	1 (0.6)						
Constipation	7 (0.7)	10 (1.1)	72 (34.6)			0	3 (1.5)			
Dehydration	43 (4.6)	20 (2.1)								
Diarrhoea	15 (1.6)	13 (1.4)	32 (15.4)			3 (1.7)	2 (1.0)			
Dizziness		24 (11.5)	1 (0.6)	2 (1.3)		0	0			
Dyspnoea	43 (4.6)	32 (3.4)	4 (2.6)	4 (2.6)		5 (2.8)	2 (1.0)			
Fatigue	21 (2.2)	11 (1.2)	53 (25.5)			3 (1.7)	0			
Gastrointestinal problems			31 (20)	21 (13.5)						
General physical health deterioration	33 (3.5)	36 (3.8)	2 (1.3)	4 (2.6)						
Haematuria	32 (3.4)	50 (5.3)								
Hepatic failure	13 (1.4)	6 (0.6)	1 (0.6)	0						
Hydronephrosis	22 (2.3)	15 (1.6)								
Increased LDH			25 (16.1)	0						
Muscular weakness	10 (1.1)	4 (0.4)								
Myalgia		37 (17.8)								
Myocardial infarction	10 (1.1)	13 (1.4)								
Nausea	12 (1.3)	16 (1.7)	77 (37.0)	3 (8.3)	7 (17.9)	9 (32.1)	12 (41.4)	5 (2.8)	3 (1.5)	

continued

TABLE 127 Prostate cancer adverse events (continued)

Adverse events	CSR Fizazzi	Saad 2002 ¹¹⁷	Dearnaley 2003 ⁷⁹	Elomaa 1992 ⁸⁰	KyImala 1997 ⁸³	Small 2003 ⁸⁷	^a Walter 2008 ¹⁶⁰	^a Garcia-Saenz 2007 ¹⁴⁴	^a Oh 2007 ¹⁵²	^a Bamias 2005 ⁶²
Oedema, peripheral	13 (1.4)	8 (0.8)	27 (13.0)							
Performance status, decreased	10 (1.1)	2 (0.2)								
Pleural effusion	16 (1.7)	12 (1.3)								
Pneumonia	47 (5.0)	26 (2.8)								
Pulmonary embolism	24 (2.5)	17 (1.8)								
Pyrexia	21 (2.2)	26 (2.8)	27 (13.0)			3 (1.7)	1 (0.5)			
Respiratory failure	25 (2.7)	14 (1.5)								
Sepsis	13 (1.4)	11 (1.2)								
Thrombocytopenia	12 (1.3)	5 (0.5)								
Urinary tract infection	33 (3.5)	40 (4.2)								
Vomiting	27 (2.9)	26 (2.8)	43 (20.7)							
Weight decrease		26 (12.5)								

Clod*: clodronate 2.08 g per day orally; Clod**: clodronate 3.2 g initially then 1.6 g; D, denosumab 120 mg 4-weekly; NR, not reported; P, disodium pamidronate 90 mg intravenous 4-weekly; PL, placebo; VB, various BPs; Z, zoledronic acid 4 mg 4-weekly.

^a Observational studies.